EUVIMEDEUVIMED entdecken
Open Access

mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance

Chiwen Bu, Ligang Zhao, Lishan Wang, Zeqian Yu, Jiahua Zhou

Oncology Research · 2023 · 31 (4) · 495-503

DOI: 10.32604/or.2023.029309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2023. Verfasst von Chiwen Bu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pancreatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer is one of the most aggressive cancers with a median survival time of less than 5 months, and conventional chemotherapeutics are the main treatment strategy. Poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for BRCA1/2-mutant pancreatic cancer, opening a new era for targeted therapy for this disease. However, most pancreatic cancer patients carry wild-type BRCA1/2 with resistance to PARP inhibitors. Here, we reported that mammalian target of rapamycin complex 2 (mTORC2) kinase is overexpressed in pancreatic cancer tissues and promotes pancreatic cancer cell growth and invasion. Moreover, we found that knockdown of the mTORC2 obligate subunit Rictor sensitized pancreatic cancer cells to the PARP inhibitor olaparib. Mechanistically, we showed that mTORC2 positively regulates homologous recombination (HR) repair by modulating BRCA1 recruitment to DNA double-strand breaks (DSBs). In addition, we confirmed that combination treatment with the mTORC2 inhibitor PP242 and the PARP inhibitor olaparib synergistically inhibited pancreatic cancer growth in vivo. Thus, this study provides a novel target and strategy for optimizing PARP inhibitor efficiency in pancreatic cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPancreatic NeoplasmsHumansPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinCell Line, TumorBRCA2 ProteinPoly(ADP-ribose) Polymerases

Stichwörter der Autor:innen

DNA damageHR repairPARP inhibitorsPancreatic cancermTORC2

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 ProteinAntineoplastic AgentsPoly(ADP-ribose) Polymerases

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
  • School of Medicine, Southeast University, Nanjing, 210009, China.

Zitieren

APA

Bu, C., Zhao, L., Wang, L., Yu, Z., & Zhou, J. (2023). mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance. Oncology Research, 31(4), 495-503. https://doi.org/10.32604/or.2023.029309

Vancouver

Bu C, Zhao L, Wang L, Yu Z, Zhou J. mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance. Oncology Research. 2023;31(4):495-503. doi:10.32604/or.2023.029309

BibTeX
@article{Bu2023,
  author = {Bu, Chiwen and Zhao, Ligang and Wang, Lishan and Yu, Zeqian and Zhou, Jiahua},
  title = {mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance},
  journal = {Oncology Research},
  year = {2023},
  volume = {31},
  number = {4},
  pages = {495--503},
  doi = {10.32604/or.2023.029309}
}
Kostenlos starten →